MetalloBio, as a pioneering biotechnology company developing a new generation of antibiotics to combat drug-resistant infections, is pleased to announce the appointment of Dr. Eddy Littler as Chairman of the Board.

Dr Littler brings extensive leadership experience in the life sciences and pharmaceutical industries, having held executive and advisory roles in pharmaceutical and biotech companies. With a distinguished career focused on advancing breakthrough therapies in infectious diseases, his expertise will be important in helping to guide MetalloBio’s strategic growth and clinical development initiatives.

MetalloBio is at the forefront of addressing the global antimicrobial resistance crisis with its novel metal-based antibiotic platform. Our company’s technology aims to overcome existing drug resistance mechanisms and effectively treat life-threatening bacterial infections. Dr Littler's appointment comes at a crucial time as the company prepares to advance its pipeline towards clinical trials and forge strategic partnerships within the healthcare ecosystem.

“We are thrilled to welcome Eddy Littler as Chairman,” said Dr Michael Murray, CEO of MetalloBio. “His vast industrial knowledge and leadership will be invaluable as we accelerate the development of our innovative antibiotic solutions. His appointment strengthens our mission to bring next-generation therapies to patients in urgent need.”

Commenting on his new role, Dr. Littler said: “I am excited to join MetalloBio at this pivotal stage in its journey. Antibiotic resistance is one of the most pressing challenges in global health today, and MetalloBio’s cutting-edge approach has the potential to make a meaningful impact. I look forward to working with the team to drive the company’s success and deliver much-needed solutions to the market.”

MetalloBio continues to expand its research and development efforts, advancing its proprietary platform to address the urgent and growing threat of antimicrobial resistance. With Dr. Littler’s leadership, the company is poised to strengthen its position as a leader in next-generation antibiotic innovation.

‍